

INDOLAMINE 2,3-DIOXYGENASE (IDO) LEVELS IN LEPROSY PATIENTS WITH POSITIVE SEROLOGY

Ago Harlim¹, M. Zen Rahfiludin²

¹Faculty of Medicine, Universitas Kristen Indonesia, Indonesia

²Faculty of Public Health, Universitas Diponegoro, Indonesia
agoharlim@yahoo.com

INTRODUCTION

Seropositive leprosy individuals have a tendency to experience a change into leprosy lepromatous type. Previous studies have demonstrated that the activity of indoleamine 2, 3-dioxygenase (IDO) in patients with lepromatous type leprosy is higher than those with tuberculoid type leprosy. However, no study has been available showing how IDO level can be correlated to seropositive subjects.

METHOD

Our observational cross-sectional study was conducted in Brebes, Central Java, Indonesia. Leprosy seropositivity was determined by measuring the level of anti-phenolic glycolipid-1 Ig M and IDO level using ELISA.

RESULTS & DISCUSSION

Higher level of IDO found in seropositive leprosy subjects of our study supported the results of previous studies which indicate a high IDO protein expression in lepromatous skin lesions and high IDO activity in the sera of lepromatous leprosy patients. People who live together under one and the same roof with leprosy patients with seropositive anti-PGL-I antibody have higher risk for developing leprosy (particularly the lepromatous type) compared to those who have contact with seronegative patients.

Table 1 Subject characteristics and indoleamine 2, 3-dioxygenase (IDO) levels.

Variables	Seropositive leprosy (n=29)	Seronegative leprosy (n=30)	P
Sex			
Male (%)	20.7	33.3	0.275 ^a
Female (%)	79.3	66.7	
Level of education			
Primary education (%)	82.8	80.0	0.786 ^a
Higher education (%)	17.2	20.0	
Age (years), (mean + SD)	33 ± 10	35 ± 11	0.399 ^b
IDO (pg/mL), (median + SD)	13.80 ± 9.13	9.10 ± 4.60	0.048 ^c

a=chi-square test, b= independent t-test, c=Mann-Whitney test

CONCLUSION

In the early stage of leprosy infection, a high level of IDO level can already be found; therefore, it can affect immune response and ultimately affecting further course of the disease

REFERENCE

1. de Souza Sales J, Lara FA, Amadeu TP, de Oliveira Fulco T, da Costa Nery JA, Sampaio EP et al. The role of indoleamine 2, 3-dioxygenase in lepromatous leprosy immunosuppression. Clin Exp Immunol. 2011;165:251-63.
2. Moet FJ, Meima A, Oskam L, Richardus JH. Risk factors for the development of clinical leprosy among contacts, and their relevance for targeted interventions. Lepr Rev. 2004;75:310-32.
3. Douglas JT, Cellona RV, Fajardo TT Jr, Abalos RM, Balagon MV, Klaster PR. Prospective study of serological conversion as a risk factor for development of leprosy among household contacts. Clin Diag Lab Immunol. 2004;11:897- 900.
4. Becerra A, Warke RV, Xhaja K, Evans B, Evans J, Martin K et al. Increased activity of indoleamine 2, 3-dioxygenase in serum from acutely infected dengue patients linked to gamma interferon antiviral function. J Gen Virol. 2009;90:810-7.
5. Rahfiludin MZ, Kartasurya MI, Purwaningsih E. The different levels of interferon gamma capacity production on several stages of leprosy. Med J Indones. 2007;16:224-7.



INDOLAMINE 2,3-DIOXYGENASE (IDO) LEVELS IN LEPROSY PATIENTS WITH POSITIVE SEROLOGY

World Congress of Dermatology Milan 2019

Ago Harlim¹, M. Zen Rahfiludin²

¹Faculty of Medicine, Universitas Kristen Indonesia, Indonesia

²Faculty of Public Health, Universitas Diponegoro, Indonesia
agoharlim@yahoo.com

INTRODUCTION

Our observational cross-sectional study was conducted in Brebes, Central Java, Indonesia. Leprosy seropositivity was determined by measuring the level of anti-phenolic glycolipid-1 Ig M and IDO level using ELISA.

RESULTS & DISCUSSION

Seropositive leprosy individuals have a tendency to experience a change into leprosy lepromatous type. Previous studies have demonstrated that the activity of indoleamine 2, 3-dioxygenase (IDO) in patients with lepromatous type leprosy is higher than those with tuberculoid type leprosy. However, no study has been available showing how IDO level can be correlated to seropositive subjects.

METHOD

Higher level of IDO found in seropositive leprosy subjects of our study supported the results of previous studies which indicate a high IDO protein expression in lepromatous skin lesions and high IDO activity in the sera of lepromatous leprosy patients. People who live together under one and the same roof with leprosy patients with seropositive anti-PGL-I antibody have higher risk for developing leprosy (particularly the lepromatous type) compared to those who have contact with seronegative patients.

Table 1 Subject characteristics and indoleamine 2, 3-dioxygenase (IDO) levels.

Variables	Seropositive leprosy (n=29)	Seronegative leprosy (n=30)	P
Sex			
Male (%)	20.7	33.3	0.275 ^a
Female (%)	79.3	66.7	
Level of education			
Primary education (%)	82.8	80.0	0.786 ^a
Higher education (%)	17.2	20.0	
Age (years), (mean + SD)	33 ± 10	35 ± 11	0.399 ^b
IDO (pg/mL), (median + SD)	13.80 ± 9.13	9.10 ± 4.60	0.048 ^c

a=chi-square test, b= independent t-test, c=Mann-Whitney test

CONCLUSION

In the early stage of leprosy infection, a high level of IDO level can already be found; therefore, it can affect immune response and ultimately affecting further course of the disease

REFERENCE


1. de Souza Sales J, Lara FA, Amadeu TP, de Oliveira Fulco T, da Costa Nery JA, Sampaio EP et al. The role of indoleamine 2, 3-dioxygenase in lepromatous leprosy immunosuppression. Clin Exp Immunol. 2011;165:251-63.
2. Moet FJ, Meima A, Oskam L, Richardus JH. Risk factors for the development of clinical leprosy among contacts, and their relevance for targeted interventions. Lepr Rev. 2004;75:310-32.
3. Douglas JT, Cellona RV, Fajardo TT Jr, Abalos RM, Balagon MV, Klaster PR. Prospective study of serological conversion as a risk factor for development of leprosy among household contacts. Clin Diag Lab Immunol. 2004;11:897- 900.
4. Becerra A, Warke RV, Khaja K, Evans B, Evans J, Martin K et al. Increased activity of indoleamine 2, 3-dioxygenase in serum from acutely infected dengue patients linked to gamma interferon antiviral function. J Gen Virol. 2009;90:810-7.
5. Rahfiludin MZ, Kartasurya MI, Purwaningsih E. The different levels of interferon gamma capacity production on several stages of leprosy. Med J Indones. 2007;16:224-7.



24TH WORLD CONGRESS
OF DERMATOLOGY
MILAN 2019

10 - 15 JUNE 2019
MILAN, ITALY

A new **ERA** for global **Dermatology**
In Memory of Professor Sergio Chimenti



WCD2019 Daily Newspaper



24TH WORLD CONGRESS
OF DERMATOLOGY
MILAN 2019

A new **ERA** for global **Dermatology**
10 - 15 JUNE 2019

Scientific Programme Committee

Dear Friends and Colleagues,

The Scientific Programme Committee of the 2019 World Congress of Dermatology is delighted to welcome you to Milan. We believe we have assembled an innovative, wide-ranging and truly global programme of symposia, workshops, courses and controversies delivered by the leading specialists in their fields. This is

News from
WCD2019

[CONGRESS PROGRAMME](#)

delighted to welcome you to Milan. We believe we have organized an innovative wide-ranging and truly global programme of symposia, workshops, courses and controversies delivered by the leading specialists in their fields. This is complemented by invited and keynote plenary speakers of the very highest calibre. Our objective is to deliver an accessible blend of clinical, practical and scientific education that will allow you to better manage your patients wherever they may be around the world.



Professor Christopher Griffiths OBE MD FMedSci

CONGRESS PROGRAMME

ABSTRACT BOOK

According to the WCD 2019 policy, only participants who are older than 18 years old are admitted. No minor child will be allowed to access the congress center.

Follow us on...



Social Wall

Professor Christopher Griffiths OBE MD FMedSci



Social Wall

ILDS/WCD2019 SCIENTIFIC PROGRAMME COMMITTEE

Christopher Griffiths (UK), Chair
Jean L. Bologna (USA)
Raul Cabrera (Chile)
Lars E. French (Germany)
Hassan Galadari (United Arab Emirates)
Kenji Kabashima (Japan)
Harvey Lui (Canada)
Giovanni Pellacani (Italy)
Ketty Peris (Italy)
Martin Röcken (Germany)
Jerry Shapiro (Canada)



Photogallery



Videogallery



Hotel rooms are



Social Event at

DAILY 11 JUNE

DAILY 12 JUNE

DAILY 13 JUNE

DAILY 14 JUNE

DAILY 15 JUNE

Welcome to **Milan**. Welcome to **WCD2019**.

The Italian Society of Dermatology (SIDeMaST) is honored to host the 24th World Congress of Dermatology (WCD) in Milan from June 10-15, 2019. It will be held under the auspices of the International League of Dermatological Societies.

We are very proud that this prestigious event will again take place in Italy, as it has been over 40 years since we last hosted the world's dermatologists. Milan has a rich historic heritage, dating back to when it was the capital of the Western Roman Empire. While in Milan, Leonardo da Vinci, the quintessential Renaissance artist and scientist, drew his iconic Vitruvian man and painted the world renowned Last Supper. The city is adorned with many gorgeous buildings, from both the past and the present...

[read more](#)

The first large scale international gathering of dermatologists took place in Paris in 1889. Since that historic inaugural event, the World Congress of Dermatology has been held on 23 occasions, and currently takes place only once every four years under the auspices of *International League of Dermatological Societies*. For its 130th anniversary in 2019, the World Congress of Dermatology will return to its European roots where we will be hosted in Milan by the Italian Society of Dermatology. The 24th World Congress of Dermatology will bring together international experts to share professional experiences, knowledge, and skills for improving patient care. WCD 2019 will also attract thousands of participants from the 180 global societies that now make up the ILDS.

This Congress has been many years...
[read more](#)

News from **WCD2019**

[CONGRESS PROGRAMME](#)

[ABSTRACT BOOK](#)

According to the WCD 2019 policy, only participants who are older than 18 years old are admitted. No minor child will be allowed to access the congress center.

20. Nutrition and dermatology migration health

21. Hyperhidrosis

22. Infectious diseases (bacterial, fungal, viral, parasitic, infestations)

23. Inflammatory skin diseases (other than atopic dermatitis & psoriasis)

24. Lasers

25. LGBT Health

26. Medical therapies and pharmacology

27. Melanoma and melanocytic naevi

28. Mucosal diseases (oral, anogenital), external eye disease

29. Nail disorders

30. Paediatric dermatology

31. Photobiology and Photoprotection

32. Phototherapy, photodynamic therapy

33. Pigmentation

34. Pruritus

35. Psoriasis

36. Psychodermatology

37. Quality of Life, Quality of Care, and Patient Safety

THE ROLE OF TRANSFORMING GROWTH FACTOR-B AND IMMUNOGLOBULIN-M ANTI PHENOLIC GLYCOLIPID-1 IN THE RECURRENCE OF ERYTHEMA NODOSUM LEPROSUM

Muhammad Syafei Hamzah, Raden Pamudji -

A CASE OF RHEUMATOID ARTHRITIS PATIENT WITH DISSEMINATED TALAROMYCES MARNEFFEI INFECTION

Rui Han, Hao Cheng

SKIN INFECTIONS DUE TO ATYPICAL MYCOBACTERIA IN IMMUNOCOMPETENT PATIENTS: EXPERIENCE FROM INDIA

Sanjeev Handa

INDOLEAMINE 2, 3-DIOXYGENASE (IDO) LEVELS IN LEPROSY PATIENTS WITH POSITIVE SEROLOGY

Ago Harlim, Zen Rahfiludin

GENITAL WARTS: A COMPARATIVE TREATMENT BETWEEN LIQUID NITROGEN AND KOH 5%

F Hassan, L Saoud

DERMATOLOGIC MANIFESTATIONS AMONG HUMAN IMMUNODEFICIENCY VIRUS PATIENTS IN MOROCCO AND ASSOCIATION WITH IMMUNE STATUS

Titou Hicham, Boui Mohammed, Hjjira Naoufal

FACTORS ASSOCIATED WITH UNSUPPRESSED VIRAL LOAD IN HIV-1-INFECTED PATIENTS ON FIRST LINE ANTIRETROVIRAL THERAPY IN MOROCCO

Titou Hicham, Frikh Rachid, Boui Mohammed, Hjjira Naoufal



24TH WORLD CONGRESS
OF DERMATOLOGY
MILAN 2019



Proudly presented under
the auspices of the International
League of Dermatological Societies

This is to certify that the Abstract titled

**INDOLEAMINE 2, 3-DIOXYGENASE (IDO) LEVELS IN LEPROSY
PATIENTS WITH POSITIVE SEROLOGY**

Ago Harlim ⁽¹⁾ - Zen Rahfiludin ⁽²⁾

Medical Faculty, Christian University Of Indonesia, Departemen Of Dermatovenereology, Indonesia, Indonesia ⁽¹⁾
- Diponegoro University, Faculty Of Public Health, Indonesia, Indonesia ⁽²⁾

Has been presented **as e-Poster** during the 24th World Congress of Dermatology held in Milan from 10 to 15 June 2019.

Best regards,

Giovanni Pellacani, MD
President, WCD 2019

President: Giovanni Pellacani
Secretary-General: Ketty Peris

Organising secretariat
TriumphGroup

Via Lucilio, 60 - 00136 Rome, Italy
wcd2019milan@thetriumph.com

www.wcd2019milan.org





INFECTIOUS DISEASES (BACTERIAL, FUNGAL, VIRAL, PARASITIC, INFESTATIONS)

INDOLEAMINE 2, 3-DIOXYGENASE (IDO) LEVELS IN LEPROSY PATIENTS WITH POSITIVE SEROLOGY

Ago Harlim⁽¹⁾ - Zen Rahfiludin⁽²⁾

Medical Faculty, Christian University Of Indonesia, Departemen Of Dermatovenereology, Indonesia, Indonesia⁽¹⁾ - Diponegoro University, Faculty Of Public Health, Indonesia, Indonesia⁽²⁾

Background: Seropositive leprosy individuals have a tendency to experience a change into leprosy lepromatous type. Previous studies have demonstrated that the activity of indoleamine 2, 3-dioxygenase (IDO) in patients with lepromatous type leprosy is higher than those with tuberculoid type leprosy.

Objectives : To know the level of IDO in seropositive subjects.

Materials and methods: Our observational cross-sectional study was conducted in Brebes, Central Java, Indonesia. Leprosy seropositivity was determined by measuring the level of anti-phenolic glycolipid-1 IgM and IDO level using ELISA.

Result: Result of The IDO level in seropositive leprosy subjects was higher compared to those who were seronegative (p = 0.048).

Conclusion: In the early stage of leprosy infection, a high level of IDO level can already be found; therefore, it can affect immune response and ultimately affecting further course of the disease.

Keywords: 3-dioxygenase, anti-phenolic glycolipid-1 IgM, indoleamine 2, seropositive leprosy



INDOLAMINE 2,3-DIOXYGENASE (IDO) LEVELS IN LEPROSY PATIENTS WITH POSITIVE SEROLOGY

Ago Harlim¹, M. Zen Rahfiludin²

¹Faculty of Medicine, Universitas Kristen Indonesia, Indonesia

²Faculty of Public Health, Universitas Diponegoro, Indonesia

agoharlim@yahoo.com

INTRODUCTION

Seropositive leprosy individuals have a tendency to experience a change into leprosy lepromatous type. Previous studies have demonstrated that the activity of indoleamine 2, 3-dioxygenase (IDO) in patients with lepromatous type leprosy is higher than those with tuberculoid type leprosy. However, no study has been available showing how IDO level can be correlated to seropositive subjects.

METHOD

Our observational cross-sectional study was conducted in Brebes, Central Java, Indonesia. Leprosy seropositivity was determined by measuring the level of anti-phenolic glycolipid-1 Ig M and IDO level using ELISA.

RESULTS & DISCUSSION

Higher level of IDO found in seropositive leprosy subjects of our study supported the results of previous studies which indicate a high IDO protein expression in lepromatous skin lesions and high IDO activity in the sera of lepromatous leprosy patients. People who live together under one and the same roof with leprosy patients with seropositive anti-PGL-I antibody have higher risk for developing leprosy (particularly the lepromatous type) compared to those who have contact with seronegative patients.

Table 1 Subject characteristics and indoleamine 2, 3-dioxygenase (IDO) levels.

Variables	Seropositive leprosy (n=29)	Seronegative leprosy (n=30)	P
Sex			
Male (%)	20.7	33.3	0.275 ^a
Female (%)	79.3	66.7	
Level of education			
Primary education (%)	82.8	80.0	0.786 ^a
Higher education (%)	17.2	20.0	
Age (years), (mean + SD)	33 ± 10	35 ± 11	0.399 ^b
IDO (pg/mL), (median + SD)	13.80 ± 9.13	9.10 ± 4.60	0.048 ^c

a=chi-square test, b= independent t-test, c=Mann-Whitney test

CONCLUSION

In the early stage of leprosy infection, a high level of IDO level can already be found; therefore, it can affect immune response and ultimately affecting further course of the disease

REFERENCE

1. de Souza Sales J, Lara FA, Amadeu TP, de Oliveira Fulco T, da Costa Nery JA, Sampaio EP et al. The role of indoleamine 2, 3-dioxygenase in lepromatous leprosy immunosuppression. Clin Exp Immunol. 2011;165:251-63.
2. Moet FJ, Meima A, Oskam L, Richardus JH. Risk factors for the development of clinical leprosy among contacts, and their relevance for targeted interventions. Lepr Rev. 2004;75:310-32.
3. Douglas JT, Cellona RV, Fajardo TT Jr, Abalos RM, Balagon MV, Klaster PR. Prospective study of serological conversion as a risk factor for development of leprosy among household contacts. Clin Diag Lab Immunol. 2004;11:897- 900.
4. Becerra A, Warke RV, Khaja K, Evans B, Evans J, Martin K et al. Increased activity of indoleamine 2, 3-dioxygenase in serum from acutely infected dengue patients linked to gamma interferon antiviral function. J Gen Virol. 2009;90:810-7.
5. Rahfiludin MZ, Kartasurya MI, Purwaningsih E. The different levels of interferon gamma capacity production on several stages of leprosy. Med J Indones. 2007;16:224-7.

From: WCD 2019 <wcd2019abstract@thetriumph.com>

Subject: WCD 2019_Poster acceptance

Date: 3 January 2019 21.55.49 GMT+7

To: agoharlim@yahoo.com

Reply-To: wcd2019abstract@thetriumph.com

[If you do not visualize this message correctly, please click here](#)



24TH WORLD CONGRESS
OF DERMATOLOGY
MILAN 2019
PLATINUM Sponsor



International League
of Dermatological Societies
Skin Health for the World

Dear Ago Harlim,

Thank you for submitting your abstract for presentation at the 24th World Congress of Dermatology to be held from 10 to 15 June 2019 in Milan, Italy.

On behalf of the Scientific Committee we are pleased to inform you that your Abstract(s) **330 Indoleamine 2, 3-dioxygenase (IDO) levels in leprosy patients with positive serology - 327 Classification of Foreign Body Reactions due to Industrial Silicone Injection** has been selected as e-Poster.

Further information about the e-Poster procedures and submission will be available by the end of January 2019 on the Congress website www.wcd2019milan.org

Looking forward to seeing you in Milan.
Best regards,

The Organizing Secretariat



● wcd2019abstract@thetriumph.com
Kepada: agoharlim@yahoo.com



5 Jul 2018 jam 12.29



Abstract Submission Confirmation

24^o World Congress of Dermatology - WCD 2019

June 10 - 15, 2019, Milano, MiCo Milano Congressi

Congratulations! Your abstract entitled

"Indoleamine 2, 3-dioxygenase (IDO) levels in leprosy patients with positive serology"

has been successfully submitted and your data have been properly uploaded.

Please find below your login details that will allow you check the status of your abstract.

Please take note that the same login details may be used to modify the abstract, once uploaded. All the changes must be submitted not later than **15 September, 2018.**

Indoleamine 2, 3-dioxygenase (IDO) levels in leprosy patients with positive serology

Ago Harlim

Universitas Kristen Indonesia

Introduction

Leprosy still remains a major public health problem in Indonesia since the incidence of leprosy is relatively high.¹ It is possibly due to contact with seropositive leprosy patients that have been turning into manifest leprosy.

Measuring the level of anti-phenolic glycolipid-1 immunoglobulin M (PGL-1 IgM) is one of the methods to detect seropositive leprosy subjects.^{2,3} The level of such cellular immune response will determine leprosy spectrum. The cellular immunity in leprosy tuberculoid type is still good, on the contrary, there is decreased cellular immunity in leprosy lepromatous type.⁴ Individuals with seropositive leprosy contact (IgM anti-PGL-1 level more than 600 unit/ml), have a tendency to experience a change into leprosy lepromatous type.

Previous studies have demonstrated that leprosy patients with lepromatous type have a higher activity of indoleamine 2, 3-dioxygenase (IDO) compared to those with tuberculoid type. The role of IDO levels in leprosy has been studied and an increased number of macrophages/dendritic cells (DC-lineage IDO+ cells were found in lepromatous (LL) compared to tuberculoid (BT) and reversal reaction massive macrophage infiltration containing a variable number of Virchow cells, full of bacilli accompanied by few lymphocytes, separated from the flat epidermis by a clear zone. BT lesions were characterized by an organized dermal granuloma composed of phagocytic cells with evident epithelioid differentiation surrounded by lymphocytes of giant cells. RR lesions showed activated macrophages with an epithelioid appearance, organized or not as granuloma.⁵

However, no study has been conducted to evaluate how IDO level can be correlated to seropositive leprosy subjects (IgM anti PGL – 1 level more than 600 unit/ml) and have not showed a clinical manifestation on the skin. Our study aimed to identify the difference of IDO level between seropositive and seronegative leprosy subjects.

Methods

Our study was an observational study using a cross-sectional method. In August 2015, the study was conducted in Brebes, Central Java, Indonesia. Ethical clearance was approved by the Ethics Committee of Medical and Public Health Research, Faculty of Public Health, Diponegoro University.

The eligible subjects participated in our study were those who fulfilled the inclusion criteria: individuals who were living together with a leprosy patient, age between 15-55 years, showed no clinical symptom of leprosy, were not taking immunosuppressants during the last three months prior to the study and those who were willing to participate in our study. They also did not suffer from tuberculosis and did not take any anti-tuberculosis medications. The subjects were divided into 2 groups, i.e. those with seropositive leprosy (anti PGL-1 IgM > 600 unit/mL) 6 and those who were seronegative. Five milliliters of venous blood was drawn from each subject. The whole blood was centrifuged to separate the serum, which was then stored at – 70°C. Seropositive leprosy was determined by measuring the levels of anti-PGL-1 IgM antibodies using enzyme-

linked immunosorbent assay (ELISA) (Polyclonal rabbit anti-human IgM/HRP (Dako ®) and analyzing IDO levels using ELISA commercial kits (Cusabio®, Catalog No: CSB-E09966h). All tests were conducted at the Institute Tropical Disease Laboratory, Airlangga University, Surabaya.

The education level of subjects was categorized into 2 groups, i.e. basic and moderate education. Subjects in basic education group were those who had completed their elementary and junior high school; while moderate education group involved those with senior high school educational background

Results

Table 1 shows that the gender, level of education and age had no effect on the seropositivity (anti-PGL-1 IgM antibodies levels) in leprosy patients; but the levels of IDO were significantly different between seropositive leprosy with seronegative subjects ($p = 0.048$).

In sex variable, there were 20.7% male and 79.3% female with seropositive leprosy and 33.3% male and 66.7% female with seronegative leprosy. There is no significant difference between seropositive leprosy subjects and seronegative leprosy subjects in sex variable ($p = 0.275$).

Table 1 Subject characteristics and indoleamine 2, 3-dioxygenase (IDO) levels. <i>Variables</i>	<i>Seropositive leprosy</i> ($n=29$)	<i>Seronegative leprosy</i> ($n =30$)	<i>P</i>
Sex			
Male (%)	20.7	33.3	0.275a
Female (%)	79.3	66.7	
Level of education			
Primary education (%)	82.8	80.0	0.786a
Higher education (%)	17.2	20.0	
Age (years), (mean + SD)	3 ± 10	35 ± 11	0.399b
IDO (pg/mL), (median + SD)	13.80 ± 9.13	9.10 ± 4.60	0.048c

a=chi-square test, b=independent t-test, c=Mann-Whitney test

In level of education variable, seropositive leprosy subjects in primary education is 82.8% and 17.2% is in higher

education while in (RR) patients. LL lesions were characterized by Seronegative leprosy subjects there were 80% in primary education and 20% in higher education ($p = 0.786$) The mean age of seropositive leprosy subjects was 33 ± 10 years and the mean age of seronegative leprosy subjects was 35 ± 11 years. ($p = 0.399$) The mean IDO level in seropositive leprosy subject was 13.80 ± 9.13 pg/mL while that in seronegative leprosy subject was 9.10 ± 4.60 pg/mL. There was significant difference between seropositive leprosy and seronegative leprosy subjects in terms of IDO level ($p=0.048$).

Discussion

The first body mechanical defense against *Mycobacterium leprae* is by activating the antigen presenting cells (APCs) of immune system, i.e. the dendritic cells, monocytes and macrophages. IDO is predominantly expressed in APCs. Interferon gamma (IFN- γ) and dependent and/or independent signal pathways can activate and mediate IDO.⁷

Higher level of IDO found in seropositive leprosy subjects of our study supported the results of previous studies which indicate a high IDO protein expression in lepromatous skin lesions and high IDO activity in the sera of lepromatous leprosy patients.⁵ People who live together under one and the same roof with leprosy patients with seropositive anti-PGL-I antibody have higher risk for developing leprosy (particularly the lepromatous type) compared to those who have contact with seronegative patients. The anti-PGL-I antibody level in people who live together under one and the same roof with leprosy indicates increased risk of having leprosy in the next 4 years. Another study in Philippines showed an increased risk of developing leprosy to 24-fold is caused by seropositive contacts.^{8,9}

In addition due to *M. leprae*, the increased IDO activity in the sera of lepromatous leprosy patients also depends on IFN- γ . There is also a statement that IDO activity was at least partially dependent upon IFN- γ from a study in dengue patients.¹⁰ IDO can be induced in response to various stimuli. The most potent inducer is IFN- γ , although other inflammatory stimuli, including type-I interferons (IFN- α/β) and bacterial lipopolysaccharide (LPS), and some viruses and intracellular pathogens, can induce IDO expression.¹⁵ Support for the "two signal" requirement for IDO-expression has also been obtained in human samples.¹⁴ For example, human monocytes expressed IDO in lepromatous leprosy due to the synergistic actions of IFN- γ and the bacterium (likely through pattern recognition receptor signaling).⁵ *M. leprae* and IFN- γ is a cause of an increased of IDO expression in monocytes leprosy patients lepromatous type.⁵ Leprosy patients with clinical manifestation of leprosy or those with seronegative leprosy have a less IFN- γ level than seropositive leprosy.¹¹

A higher IDO level in seropositive group found in our study supports the results of some previous studies, which showed that IDO induction after bacterial infection could be beneficial to the host. Amino acid tryptophan will break into stable metabolite called kynurenine when the IDO level increases.¹² Moreover, tryptophan depletion and starvation will occur since bacteria need tryptophan.^{13,14} The growth of bacteria is dependent on the greater amount of tryptophan rather than T cells.¹³

IDO could be considered to be a double-edged sword in the immune response against pathogens. Immune cells, including antigen-presenting cells like DCs, are able to express IDO in response to various stimuli.¹⁰

Acknowledgement

Our grateful thank to Prof. Indropo Agustini, MD, DV and Leprosy Study Group of Tropical Disease Centre for using the laboratory for IgM M anti-PGL-1 and IDO assay test at University of Airlangga, Surabaya. Indonesia and also to the technician of the Institute Tropical Disease (ITD) Laboratory, Iswayudi SKM; Dinar Adriaty, S.Si, M. Kes; Ratna Wahyuni S.Si, M. Kes who examined IgM anti-PGL-1 and IDO.

References

1. World Health Organization (WHO). Global leprosy update, 2013; reducing diseases burden. *Wkly Epidemiol Res.* 2014;**89**:389-400.
2. Agusni I, Adriaty D, Wahyuni R, Izumi S. Correlation between the sero-positivity level and new case detection rate (NCDR) in some leprosy endemic areas of Indonesia. *Jpn J Lepr.* 2009;**78**:140.
3. Izumi S. Subclinical infection by *Mycobacterium leprae*. *Int J Lepr.* 1999;**67** (4) (Suppl):S67-71.
4. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. *Clin Microbiol Rev.* 2006;**19**:338-81.
5. de Souza Sales J, Lara FA, Amadeu TP, de Oliveira Fulco T, da Costa Nery JA, Sampaio EP *et al.* The role of indoleamine 2, 3-dioxygenase in lepromatous leprosy immunosuppression. *Clin Exp Immunol.* 2011;**165**:251-63.
6. Rahfiludin MZ, Pangestuti DR. *Phyllanthus niruri* extract could improve immunoglobulin-M anti phenolic glycolipid-1 level in seropositive contact of Hansen's disease patients. *J Health Res.* 2012;**26**:55-8.
7. Murakami Y, Hoshi M, Imamura Y, Arioka Y, Yamamota Y, Saito K. Remarkable role of indoleamine 2,3-dioxygenase and tryptophan metabolites in infectious diseases: potential role in macrophage-mediated inflammatory diseases. *Mediators Inflamm.* 2013;2013.
8. Moet FJ, Meima A, Oskam L, Richardus JH. Risk factors for the development of clinical leprosy among contacts, and their relevance for targeted interventions. *Lepr Rev.* 2004;**75**:310-32.
9. Douglas JT, Cellona RV, Fajardo TT Jr, Abalos RM, Balagon MV, Klaster PR. Prospective study of serological conversion as a risk factor for development of leprosy among household contacts. *Clin Diag Lab Immunol.* 2004;**11**:897-900.
10. Becerra A, Warke RV, Xhaja K, Evans B, Evans J, Martin K *et al.* Increased activity of indoleamine 2, 3-dioxygenase in serum from acutely infected dengue patients linked to gamma interferon antiviral function. *J Gen Virol.* 2009;**90**:810-7.
11. Rahfiludin MZ, Kartasurya MI, Purwaningsih E. The different levels of interferon gamma capacity production on several stages of leprosy. *Med J Indones.* 2007;**16**:224-7.
12. Harden JL, Egilmez NK. Indoleamine 2, 3-dioxygenase and dendritic cell tolerogenicity. *Immunol Invest.* 2012;**41**:738-64.
13. Muller AJ, Heseler K, Schmidt SP, Spekker K, Mackenzie CR, Däubener W. The missing link between indoleamine 2, 3-dioxygenase mediated antibacterial and immunoregulatory effects. *J Mol Med.* 2009;**13**:1125-35.
14. Njau F, Geffers R, Thalmann J, Haller H, Wagner AD. Restriction of *Chlamydia pneumoniae* replication in human dendritic cell by activation of indoleamine 2, 3-dioxygenase. *Microbes Infect.* 2009;**11**:1002-10.
15. King NJ, Thomas SR. Molecules in focus: indoleamine 2,3-dioxygenase. *Int J Biochem Cell Biol.* 2007;**39**:2167-72.

